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Background: Hepcidin is a peptide hormone belonging to the defensin family of cationic antimicrobial molecules
that has an essential role in systemic iron homeostasis. The peptide is synthesised by hepatocytes and transported
in the circulation to target tissues where it regulates the iron export function of the ferrous iron permease, ferroportin.
In the brain hepcidin protein has been identified using immuno-histochemistry and mRNA by real-time PCR but not by
in situ hybridisation raising the question of whether there is measurable transcription of the hepcidin gene in the
central nervous system. Alternatively hepcidin could be transported as a hormone to the brain via the circulation.
Results: By RT-PCR hepcidin mRNA was present at low level throughout normal rat brain while in situ hybridisation
to detect low-abundant mRNA revealed that transcripts were restricted to endothelium of blood vessels and choroid
plexus. In contrast, hepcidin protein analysed by immuno-histochemistry was highly expressed in blood vessels, in
endothelium and in pericytes. Hepcidin was also present in glial cells and in the olfactory bulb, sub-ventricular
zone and dentate gyrus, areas where neurogenesis and synaptic plasticity are maintained throughout adult life.
The hepcidin species identified by Western blotting in sub-ventricular zone, cortex and hippocampus migrated as
a ~2.8 kDa band, identical in size to hepcidin present in normal rat serum suggesting that hepcidin in brain was
the full-length biologically active 25 amino acid peptide. Hepcidin co-localised with ferroportin in ependymal
cells of the sub-ventricular zone and in the corpus callosum consistent with a regulatory role in iron metabolism
at these sites.
Conclusions: Hepcidin protein was widely expressed in brain parenchyma while levels of hepcidin gene transcription
appeared to be below the limits of detection of the in situ hybridisation probes. This disparity suggests that not all
hepcidin in the brain is transcribed in situ and may originate in part outside the brain. The properties of hepcidin as a
cationic peptide hormone are reflected in the finding of hepcidin in the walls of blood vessels and in pericytes and
glia, cells that may be involved in transporting the peptide into brain interstitium.
Keywords: Hepcidin, Ferroportin, Defensin, Inflammatory cytokines, Brain iron homeostasis, Blood brain barrier,
Pericytes, Sub-ventricular zone, NeurogenesisBackground
Iron is an essential nutrient for almost all living organ-
isms but in excess is toxic and regulatory mechanisms
have evolved to ensure that iron homeostasis is main-
tained at both the whole-body and cellular levels [1,2].
The liver-derived peptide hormone hepcidin is the
principle regulator of systemic iron homeostasis in
mammals [3-5] where it controls the flow of iron into* Correspondence: rr224@cam.ac.uk
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article, unless otherwise stated.the circulation from multiple sites including duodenal
enterocytes, iron-recycling macrophages and hepatocytes
[6]. Hepcidin is synthesised by hepatocytes in response
to iron signals, inflammation, hypoxia and endoplasmic
reticulum stress [7]. Following proteolytic processing [8],
the active hormone is distributed in the circulation to
cells expressing the hepcidin receptor, ferroportin, which
is the only known iron exporter expressed by mamma-
lian cells [9]. Hepcidin triggers the internalisation and
lysosomal degradation of ferroportin to regulate iron
export [10].d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Raha-Chowdhury et al. BMC Neuroscience  (2015) 16:24 Page 2 of 12The blood brain barrier in adult animals does not
allow the passage of free iron and the majority of iron
entering the brain does so through the binding of difer-
ric transferrin to transferrin receptors (TfR1) expressed
on the luminal surface of brain capillary endothelial cells
(BCECs) [11]. Following receptor-mediated endocytosis
iron is released from transferrin and transported across
the endosomal membrane or released from the BCECs
into brain parenchyma [12]. Recently a model of iron
transport across the BBB has been suggested [13] in
which the capillary endothelium induces underlying
astrocytes to produce ferroxidase activity to support
ferroportin-mediated iron efflux by the BCECs. Iron is
essential for growth and development of the embryonic
brain [14] and in the adult for synthesis of key en-
zymes, myelin and neurotransmitters. Recently a key
role for iron in neuronal function has been identified
with the finding that iron is essential for synaptic plas-
ticity and the associated generation of post-synaptic
Ca2+ signals [15].
How brain iron uptake is regulated and whether hepci-
din has a role is uncertain. The constitutive loss of hep-
cidin through gene mutations in either human [16] or
mouse hemochromatosis [17,18] does not appear to
cause abnormalities in brain iron levels; this raising the
question of whether there is redundancy in the function
of hepcidin in the central nervous system. We should
also consider whether the functional properties of hepci-
din as a hormone, those of production at a remote site
(the liver), with transport in the circulation to target
tissues are relevant to a potential role for the peptide in
brain iron homeostasis. If this is the case there would be
the requirement for hepcidin to cross the blood brain
barrier to gain access to brain parenchyma. It is known
that conditional inactivation of the hepcidin gene in
mouse liver recapitulates the severe iron overload seen
in the model with total hepcidin knockout [19], this
demonstrating that the hepatocyte is the major site of
hepcidin synthesis and that other tissues are unable to
compensate. Indeed, there is uncertainty over whether
hepcidin is synthesised in the brain as mRNA was not
detected in early studies by Northern analysis [4,5] and
in-situ hybridisation similarly failed to produce a consist-
ent signal [20]. Hepcidin mRNA was detected in normal
brain [20,21] and in the presence of systemic inflamma-
tion [22] using the highly sensitive technique of RT-PCR
but again transcripts were not consistently found in all
studies [23,24]. In contrast, hepcidin as an immunoreac-
tive, 25 amino acid (aa) peptide has been reported to be
expressed by neurones and astrocytes in the normal
mouse brain [20] and also induced by experimental
inflammation in the brain [22]. We have recently con-
firmed that hepcidin protein is widely expressed in all
glial cells in normal mouse brain and co-localises withferroportin in white matter tract [25]. Taken together
the results of these studies suggest that there are dis-
crepancies between the low levels of hepcidin mRNA
transcripts in regions of normal brain, and the robust
expression of the biologically active 25 aa peptide.
In the present study we report a detailed analysis of
hepcidin expression in normal rat brain to investigate
levels of mRNA and the active 25 aa peptide in neur-
onal and glial cells. To detect low-abundant mRNA a
radioactively-labelled oligonucleotide probe was de-
signed and the results compared with those obtained
using a DIG-labelled probe and RT-PCR. The distribu-
tion of the mature hepcidin peptide in different brain
regions was analysed using highly specific antibodies
and appropriate cellular markers. Our results show
that hepcidin mRNA was found only in the vascular
endothelium including choroid plexus, while hepcidin
protein was present throughout all brain cells. The
finding of abundant hepcidin protein in the brain paren-
chyma in the presence of low levels of gene transcription
is consistent with an origin for hepcidin outside the brain.
Results
Hepcidin mRNA expression in rat brain
Hepcidin mRNA expression was analysed by RT-PCR in
specific brain regions (sub-ventricular zone, olfactory
bulb, frontal cortex, hippocampus, dentate gyrus, corpus
callosum, cerebellum, amygdala, thalamus, choroid plexus
and brain stem). This analysis revealed low levels of
mRNA throughout the brain with a slightly higher signal
observed in the corpus callosum, cerebellum, choroid
plexus and sub-ventricular zone (Figure 1A-B).
To investigate the cellular localisation of hepcidin
mRNA in situ hybridisation experiments were performed
using a full-length probe (350 bp) amplified by DIG label-
ling. In adult rat brain no signal was detected in the cortex
(Figure 1C). A low-intensity signal was consistently ob-
served in blood vessels (Figure 1D) while a clear signal
was seen in choroid plexus (Figure 1E).
In order to detect low-abundant mRNA a radioactively-
labelled oligonucleotide probe was designed, this showing
strong hepcidin expression in adult rat liver (Figure 1J).
Even with the use of this probe, however, hepcidin mRNA
was not detected in cerebral cortex, hippocampus or den-
tate gyrus (Figure 1F-G). A β-actin probe used as a posi-
tive control showed strong expression in rat cerebellum
(Figure 1H). A sense hepcidin probe used to detect non-
specific binding produced no visible signal (data not
shown). In agreement with these findings mRNA was not
detected in cortex or cerebellum from normal human sub-
jects (data not shown), while a clear signal was again
present in choroid plexus (Figure 1I). Taken together these
in situ data suggest that hepcidin transcription in neurons
and glial cells in normal brain is below the detection limit
Figure 1 (See legend on next page.)
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Figure 1 Hepcidin mRNA expression analysed by RT-PCR and in situ hybridisation. A: Analysis of hepcidin mRNA expression by RT-PCR in adult
rat brain (n = 3). Gel banding pattern was - sub ventricular zone (SVZ), olfactory bulb (OB), frontal cortex (FCx), hippocampus (HC), dentate gyrus
(DG), corpus callosum (CC), cerebellum (CB) amygdala (AMD), thalamus (TH), choroid plexus (CP) and brain stem (BS). GAPDH was used as loading
control. B: Graph shows the percentage of image grayscale intensity above background (mean of three samples). Statistical significance compared
to whole brain control (dashed line). * = p < 0.05, ** = p < 0.01, *** = p < 0.005. Hepcidin mRNA expression was analysed by in situ hybridisation
using an antisense DIG-labelled hepcidin probe. mRNA was not visible in cortex (C), and only seen in blood vessels, and choroid plexus (D and E,
localisation of hepcidin mRNA indicated by arrows). To detect low-abundant mRNA an antisense radioactively labelled ([35S]-dATP) probe was
applied to coronal sections of rat cortex, hippocampus and dentate gyrus (F and G). Hepcidin mRNA was not detectable in cortical neurons. Probe
activity was confirmed by the finding of a strong signal using an antisense β-actin probe applied to a section of rat cerebellum (H). Hepcidin mRNA
was restricted to choroid plexus when the radioactive probe was applied to a section of human brain (I, indicated by arrows). A strong signal was
detected on a section of rat liver included as a positive control (J). The scale bar in C represents 50 μm in G; C to F = 100 μm; 25 μm in H and J,
70 μm in I.
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choroid plexus (Figure 1E&I) demonstrated a low level of
expression, this likely explaining the signal seen by RT-
PCR in corpus callosum and sub-ventricular zone, regions
of the brain with a rich vascular supply.
Molecular characterisation of hepcidin protein in the
brain
Hepcidin protein was quantified in homogenates pre-
pared from different brain regions and normal rat serum
by Western blotting using a specific rabbit anti-hepcidin
antibody. In the case of both brain lysates and serum
samples 20 ug of protein was loaded in each lane. This
analysis revealed a ~ 2.8 kDa band with highest intensity
in the sub-ventricular zone and cortex and lowest in the
hippocampus (Figure 2A-B). Hepcidin was detected in
rat serum as a band of the same molecular mass as seen
in brain tissue (Figure 2A). As a loading control for the
brain samples a β-actin antibody was used to re-probe
the blot and this allowed a relative comparison of hepci-
din levels in different regions of the brain (Figure 2B).
As β-actin is not present in serum (Figure 2A) a direct
comparison of hepcidin in brain and serum was not pos-
sible but as the same amount of protein was added (20
ug) we conclude that per unit weight of protein hepcidin
is at least as abundant in the cortex and sub-ventricular
zone as in serum. In human serum and CSF hepcidin
was also detected as a 2.8 kDa band together with a minor
10 kDa band representing pro-hepcidin (Figure 2C). Hep-
cidin was highly expressed in CSF. On this gel two anti-
bodies recognising an abundant serum protein (albumin)
and a less abundant protein (β2microglobulin) were used
as loading controls.
Cellular localisation of hepcidin protein in the brain
In brain sections analysed by immunohistochemistry and
viewed under low power, hepcidin immuno-reactivity was
associated with the choroid plexus and blood vessels. Hep-
cidin protein was present in the epithelial cells of the
choroid plexus but there was limited co-localisation with
the pericyte marker PDGFβR1 (Figure 3A-C). At highermagnification hepcidin was visible in the endothelial lining
of blood vessels where it co-localised with the endothelial
marker CD31 (Figure 3D-F). Hepcidin protein was
present in the sub-ventricular zone close to blood ves-
sels (Figure 3G) and did not co-localise with the glial
marker chondroitin sulphate proteoglycan neuron⁄glia
antigen 2 (NG2) (Figure 3G-I). At higher magnification
(panels H-I) hepcidin protein was present in endothelial
cells of blood vessels. There was clear co-localisation be-
tween hepcidin and ferroportin in the corpus callosum
(Figure 3J-L) and also in the ependymal cells of the sub-
ventricular zone (Figure 3M). Additional evidence for the
presence of hepcidin in vascular endothelium was the
finding of co-localisation with the endothelial marker vas-
cular endothelial growth factor (VEGF) in circumventricu-
lar organs (CVO) (Figure 3N). Although hepcidin did not
co-localise with the mature glial marker (NG2) this was
demonstrated with S100β indicating that the peptide is
expressed in glial precursor cells (Figure 3O).
Hepcidin was strongly expressed in the olfactory bulb,
granule cells of dentate gyrus and as noted above in the
white matter tract of corpus callosum, cortex and stri-
atum (Figure 4A-C). Hepcidin protein was also seen in
the cortex and hippocampus but co-localisation with the
mature neuronal marker βIII-tubulin was not observed
(Figure 4D-F). In contrast co-localisation with the ma-
ture astrocytic marker GFAP was seen confirming the
presence of hepcidin in glial cells (Figure 4G-I). Hepci-
din protein was visible in the CA region of the hippo-
campus (Figure 4H). Hepcidin protein was strongly
expressed in the walls of the lateral ventricles where it
co-localised with GFAP in astrocytic end feet in close
proximity to the ependyma (Figure 4J-L, marked with
arrow).
Discussion
The aim of this study was to investigate the expression
of hepcidin mRNA and protein in normal rat brain and
to interpret the findings in the light of the properties of
hepcidin as a peptide hormone with an essential role in
systemic iron homeostasis. A member of the defensin
Figure 2 Hepcidin protein expression in brain and serum samples.
A: Western blotting using a rabbit anti-hepcidin antibody revealed
a ~ 2.8 kDa band consistent with hepcidin protein. Lane 1: cortex 2:
sub-ventricular zone, 3: hippocampus and 4: rat serum. The highest
intensity was seen in the sub-ventricular zone and cortex and lowest
in hippocampus. Hepcidin was detected in serum as a band of same
molecular mass as seen in brain tissues. A β-actin loading control
was used to normalize data in brain tissue, this protein was absent
from serum as expected. B: Graph shows the percentage of band
intensity normalized to loading control (n = 3), * = p < 0.05, ** = p < 0.01,
*** = p < 0.005. C: In human serum (lane 1–5) hepcidin was seen as a
clear ~ 2.8 kDa band while in CSF (lane 6) hepcidin was very strongly
expressed. A weak ~ 10 kDa pro-hepcidin band was seen in all
human samples. An anti-albumin antibody and anti-β2Microglobulin
antibodies were used as loading controls. These are single experiments
to assess the antibody specificity and no statistical evaluation
was performed.
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synthesised in the liver and transported in the circula-
tion to target tissues where it controls the iron export
function of the ferrous iron permease, ferroportin [10].
The finding that hepcidin protein is present in brain in-
terstitium, specifically in neurons and glial cells [20]
raises the question of whether the peptide is produced
in situ, by transcription of the hepcidin gene, HAMP, or
transported to the brain in the circulation in the mannerof a classical hormone. Hepcidin mRNA was reported to
be present in normal mouse brain using real-time PCR
[20,21] and to be induced in rat brain by the systemic
administration of lipopolysaccharide where the increase
in hepcidin transcripts was limited to the cortex and
substantia nigra [22]. A transitory increase was also ob-
served in mouse and rat choroid plexus 3 hours after the
administration of lipopolysaccharide [27]. While hepci-
din transcripts were consistently found during inflam-
mation in this report, they were rarely detected under
basal or control conditions. Other studies have reported
an increase in hepcidin mRNA levels in the cortex,
hippocampus and striatum in a rat model of cerebral
ischemia [28] and in mouse brain following systemic
bacterial challenge [29]. In the present study we found
that hepcidin mRNA could be detected by real time PCR
at a low level throughout normal brain with a slightly
higher signal found in the corpus callosum, choroid
plexus and frontal cortex.
Real-time PCR is a highly sensitive technique that pro-
vides information on transcript levels in relatively large
areas of the brain obtained by anatomical dissection. To
investigate hepcidin transcription in more detail the cel-
lular location of the mRNA was analysed by in situ hy-
bridisation. Using a digoxigenin-labelled probe a signal
was not detectable in cortical areas but a low-intensity
signal was visible in blood vessels and a clear signal was
seen in the choroid plexus. It has previously been re-
ported using this type of probe that a low-level signal
was detectable in specific regions of normal mouse brain
including piriform cortex, facial nucleus and granule
cells of the cerebellum while a stronger signal was de-
tected in dorsal root ganglia [20]. However, in agreement
with the present study a specific mRNA signal could not
be detected in most cortical areas suggesting that tran-
scripts were of low abundance and likely to be below the
limits of detection of the probe. With the aim of detect-
ing low abundant mRNA a radioactively-labelled probe
was synthesised but even with this probe no signal was
detectable in cortical areas and transcripts were again
limited to blood vessels and choroid plexus. If hepcidin
transcription is mostly limited to vascular structures
then this could explain the findings obtained by real-
time PCR in which low levels of mRNA were detected
throughout the brain while a higher signal was observed
in regions with a rich vascular supply. Further evidence
in support of there being limited transcription of hepci-
din mRNA in neurons comes from a study of primary
cultures of brain cells using real-time PCR where mRNA
was undetectable in neurons under basal conditions and
was not induced by the addition of either inflammatory
mediators or iron. This was in contrast to cultures of as-
trocytes and microglia that responded to both conditions
with an increase in levels of hepcidin mRNA [30].
Figure 3 (See legend on next page.)
Raha-Chowdhury et al. BMC Neuroscience  (2015) 16:24 Page 6 of 12
(See figure on previous page.)
Figure 3 Localisation of hepcidin protein in rat brain endothelial cells. Double immunofluorescence (IFC) staining was performed with polyclonal
rabbit anti-hepcidin and other monoclonal antibodies with counterstaining for nuclei with DAPI (Blue). Hepcidin protein was expressed in epithelial cells
of the choroid plexus where minimal co-localisation with the pericyte marker PDGFβR1 was observed (arrow in panel A-C). At higher magnification
hepcidin was visible in the endothelial lining of blood vessels where it co-localised with the endothelial marker CD31 (D-F), but not with the
glial marker chondroitin sulphate proteoglycan neuron ⁄ glia antigen 2 (NG2) (G-I). At higher magnification hepcidin protein was visible in
blood vessel walls (H-I). Hepcidin protein was seen in the corpus callosum with some co-localisation with ferroportin noted (J-L), and a similar
finding was seen in a section of third ventricle (M). Hepcidin was present in the vascular endothelium of the circumventricular organs where
co-localisation with VEGF was seen (N). In the sub-ventricular zone hepcidin was co-localised with S100β (O). Protein expression and co-localisation
was indicated with arrow in relevant panels. The scale bar in O represents 70 μm in A and B and M; 20 μm in D-F, H and I; 50 μm in G; 30 μm in
C, J-N and O.
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gene, hepcidin protein was widely expressed throughout
the brain as demonstrated by Western blotting and im-
munohistochemistry. The hepcidin species identified by
Western blotting migrated as a ~2.8 kDa band, identical
in size to hepcidin present in rat and human serum sug-
gesting that the species in the brain was the full-length
biologically active 25 amino acid peptide. Highest levels
were found in the cortex and sub-ventricular zone with
lower levels observed in the hippocampus. The anti-
hepcidin antibody used in these experiments specifically
recognised the 2.8 kDa hepcidin species as opposed to
other antibodies that recognise both the 2.8 kDa species
and a 10 kDa peptide representing pro-hepcidin. This
form of hepcidin lacks biological activity unless it is
cleaved to yield the mature 25 amino acid peptide by
a furin-dependent process [8] and the presence of
pro-hepcidin in brain [31] is of uncertain functional
significance.
Using the specific antibody in immunohistochemistry
experiments hepcidin protein was strongly expressed in
vascular endothelium, choroid plexus and in cortical as-
trocytes with end-feet that were in close proximity to
blood vessels. Hepcidin co-localised with the endothelial
markers, CD31 and VEGF, at the luminal aspect of
blood vessels but not with the basement membrane
marker, NG2. Hepcidin was also detected on the ab-
luminal surface of endothelial tubes in pericytes, cells
that are important for the development and maintenance
of the blood–brain barrier (BBB), regulation of angio-
genesis and capillary blood flow, and regulation of the
neural response to injury [32]. The presence of hepcidin
protein in pericytes suggests a possible role for the pep-
tide in paracrine signaling. The finding of hepcidin in all
layers of the walls of blood vessels is consistent with
transport of hepcidin across the endothelial cells that
make up the BBB. Furthermore, the observation that
hepcidin was present in astrocytes intimately associated
with the outside of blood vessels suggests that glial cells
could be part of a transport pathway providing access to
brain interstitium. Hepcidin is a cationic peptide and
and evidence showing that cationic proteins readily cross
the BBB [33-36] provides further support for the notionthat hepcidin can cross the BBB under physiological
conditions. The finding that hepcidin was expressed in
the circumventricular organs would also be consistent
with a role of this organ in transporting hepcidin in to
the brain without disrupting the blood–brain barrier.
The endothelium of blood vessels and choroid plexus
demonstrated low levels of hepcidin mRNA raising the
question of whether transcription of the HAMP gene in
the brain and systemic vasculature contributes to levels
of the circulating peptide. This seems unlikely as it has
been reported that conditional inactivation of the hepci-
din gene in mouse liver recapitulates the severe iron
overload seen in animals with total hepcidin knockout
[19]. This suggests that hepatocytes are the major site of
hepcidin synthesis and other tissues such as the vascular
endothelium produces insignificant amounts of the pro-
tein and are unable to compensate for the loss of hepatic
production.
Hepcidin immunoreactivity was seen in non-vascular
structures with a consistent signal seen in glial cells but
not in mature neurons. In agreement with the results of
our previous study of normal mouse brain [25] strong
hepcidin immuno-reactivity was seen in the granule cells
of the dentate gyrus and the sub ventricular zone of
lateral ventricle. It is of interest that these two regions
are notable for having high rates of neurogenesis in adult
rats [37,38] suggesting that hepcidin may have a role in
regulating iron metabolism in newly-proliferating cells in
the mature brain. Hepcidin was also strongly expressed
by oligodendrocytes in all white matter tracts including
the rostral migratory stream, corpus callosum, cortico-
spinal tracts and cerebellar peduncles, a finding consist-
ent with the transport of this hormone along these
tracts together with other small peptide hormones and
neurotransmitters [39,40].
Conclusion
The finding of abundant hepcidin protein in brain par-
enchyma in the presence of levels of gene transcription
that appear to be below the limits of detection is consist-
ent with an origin for at least a proportion of hepcidin
outside the brain. The properties of hepcidin as a
cationic peptide hormone are reflected in the finding of
Figure 4 Cellular localisation of hepcidin protein in rat brain in neurons, astrocytes and endothelial cells. Hepcidin protein was visible in the
molecular layer and glomerular cells of the olfactory bulb (A), dentate gyrus granule cells (B), white matter tracts of corpus callosum, cortex and
striatum (C). Hepcidin was present in the upper layers of the cortex but limited expression was observed in β3 tubulin-positive neurons (D-F).
Hepcidin expression was seen in the cortex mainly in astrocytes and CA region of the hippocampus with co-localisation noted in GFAP positive
cells (G-I). Hepcidin was present in the ependymal cells of lateral ventricle (arrow) and cells within the subventricular zone where co-localisation
with GFAP in the wall of the ventricle was observed (J-L). Protein expression and co-localisation was indicated with arrow in relevant panels. The
scale bar in J represents 50 μm in A to C, J and K; 100 μm in D-I; 25 μm in B and L.
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pericytes and glia, cells that may be involved in trans-
porting the peptide into brain interstitium.
Methods
Animals
Adult Sprague–Dawley (SD) rats (12 weeks old, 180-
250 g) were purchased from Charles River. All animals
were housed under standard conditions (12 hours light–
dark cycle, 20°C ambient temperature) with free access to
food and water. All experiments were carried out in ac-
cordance with the UK Home Office Regulations for the
Care and Use of Laboratory Animals and the UK Animals
(Scientific Procedures) Act 1986.
Tissue preparation
Unfixed tissues were carefully dissected from various
brain regions from six adult rat brains and snap frozen
in dry ice until analysed by either RT-PCR or Western
blotting as described previously [41]. For histochemical
analyses, six animals were anesthetised with pento-
barbitone, flash perfused transcardially with 0.9% saline
followed by 0.1 M phosphate buffer (PBS) with 4% para-
formaldehyde (PFA) and the brains cryoprotected as
described previously [41]. A freezing microtome was
used to prepare 20 μm coronal sections through the en-
tire hippocampus, cortex, mid brains (striatum) and up
to brain stem. Sections were then stained by immuno-
histochemistry as described below.
Human brain tissues
Human brain tissues from controls (N = 6) were provided
by the UK Brain Bank. The Cambridge Health Authorities
Joint Ethics Committee for use of human brain tissue gave
ethical permission for this study. Autopsy tissue was
examined from 6 adults (age (years) 74.0 ± 8.1) as part of
another study described previously [42].
RNA isolation and RT-PCR
For RNA analysis rat brain (n = 3) tissues were dissected
from various regions (that also contain blood vessels and
endothelium) as described above. RNA was extracted
from approximately 50 mg of tissue and 1 ml of TRIzol
reagent (Invitrogen) following manufacturer’s instructions
and then purified using an RNeasy Mini kit (Qiagen).
RNA was treated with DNase I, and cDNA synthesised
from 2 μg of the treated RNA using a SuperScript III re-
verse transcriptase kit (Invitrogen) with random hexamer
primers. PCR of the newly synthesized cDNA (8 ng) was
performed using PCR Supermix (Invitrogen) with the
primer pairs for hepcidin (Forward Primer: CACAGC
AGAACAGAAGGCATG,and Reverse primer: CTTCT
GCTGTAAATGCTGT, product size 250 bp), using a
program of 95°C for 3 min, 30 cycles of 95°C for 30 s,60°C for 30 s and 72°C for 1 minute. PCR products
were separated on 2% agarose gels and photographed
under UV illumination. Transcript expression levels
were normalised to the expression of GAPDH (For-
ward Primer: CGGAGTCAACGGATTTGGTCGTAT,
Reverse primer: AGCCTTCTCCATGGTGGTGAAGAC,
product size 500 bp).
In situ hybridisation (ISH)
Brain tissues were prepared for in situ hybridisation and
probed as described previously [42]. In addition to sec-
tions of rat brains (n = 3), normal human brain sections
showing the choroid plexus were analysed. Ethical com-
mittee approval for use of this material was documented
previously [42]. Briefly, oligonucleotide probes corre-
sponding to rat hepcidin was used for radio-active label-
ling, hepcidin (Nucleotide 231–277 CTGTAAATGCTG
TAAGAATTCCTCCTGTGGTCTCTGTTGCATAAC)
was labelled with [35S]-dATP (Dupont-NEN) using a
3′-terminal deoxynucleotidyl transferase enzyme kit
(Boehringer-Mannheim), hybridization was performed
in a humid chamber overnight at 62°C (~16 h). Sections
were then washed, dehydrated and air-dried before being
exposed to Biomax MR film (Kodak) for 14 days. Non-
specific hybridization was abolished in the presence of
100-fold excess unlabelled oligonucleotide. Radioactivity
in tissue sections was analysed by dipping slides in Ilford
K-5 emulsion (Ilford, UK), followed by storage at 4°C in
light proof boxes for 56 days; they were then developed in
phenisol (Ilford), fixed and counterstained in 0.2% methy-
lene blue.
Synthesis of DIG labelled probes for ISH
To synthesize digoxigenin (DIG)-labelled RNA probes,
the target hepcidin cDNA was amplified by PCR, using
primers designed on the basis of the rat hepcidin cDNA
sequence. The primers used for DIG labelling were -
(Hepcidin-insF: TAATACGACTCACTATAGGATGGCA
CTCAGCACTCGGACC Hepcidin-insR: ATTTAGGTG
ACACTATAGACTATGTTTTGCAACAGATACC). The
PCR product was amplified using a 5′ primer containing
a T7 phage promoter sequence and a 3′ primer contain-
ing an SP6 phage promoter sequence, generating a tem-
plate for transcription of a sense and an antisense probe,
respectively. The PCR products (350 bp) were sequenced
and homology checked by BLAST search (NCBI data-
base). In vitro transcription reactions were performed
using dig-UTP RNA labelling mix (Roche, Mannheim,
Germany) and SP6 or T7 RNA polymerase (Roche) fol-
lowing the manufacturer’s instructions.
ISH with DIG labelled probe
Brain or liver sections were fixed in 4% PFA for 10 min,
permeabilized for 10 min in PBS with 0.5% Triton X-100
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of 250 mL of water with 3.5 mL of triethanolamine and
625 μL of acetic anhydride added dropwise. Pre-
hybridization was performed in hybridization buffer
made of 50% formamide, 5 × SSC and 2% blocking re-
agent (Roche) for 3 hours at 62°C. Hybridization with
dig-labelled probes (100 ng/mL) was performed in the
same buffer overnight at 62°C. Stringency washing was
performed in 0.2 × SSC for 1 hour at 62°C. For the de-
tection of dig-labelled hybrids the slides were equili-
brated in maleic acid buffer (0.1 m maleic acid and
0.15 m NaCl, pH 7.5), incubated for 1 hour at room
temperature with 1% blocking reagent made in maleic
acid buffer (blocking buffer), and then for 1 hour with
alkaline phosphatase-conjugated anti-DIG antibodies
(Roche) diluted 1:5000 in blocking buffer. The slides
were washed twice for 30 minutes in maleic acid buffer
and incubated overnight in colour development buffer
[2.4 mg levamisole (Sigma), 45 μL 4-nitroblue tetrazo-
lium (Sigma) and 35 μL 5-bromo-4-chloro-3-indolyl-
phosphate (Sigma) in 10 mL of a buffer made of 0.1 m
Trizma base, 0.1 m NaCl and 0.005 m MgCl2, pH 9.5].
The reaction was stopped in neutralizing buffer (0.01 M
Trizma base and 0.001 M EDTA, pH 8) and sections
mounted in PBS–glycerol and a coverslips applied
(Figure 1). Non-specific binding was analysed using
sense probes.
Antibodies
A polyclonal rabbit anti-hepcidin 25 (ab30760) recognis-
ing a 2.8 kDa protein [25] was used (1:200 dilution for
IHC and IF and 1:100 for WB) and all other antibodies
used are listed in Table 1. The following secondary anti-
bodies were used: Alexa Fluor 568-labelled donkey anti-
mouse, Alexa Fluor 488-labelled donkey anti-rabbit, andTable 1 List of the primary antibodies used in this study
Antibody Species
Anti-hepcidin Rabbit (polyclonal)
Anti-ferroportin Mouse (monoclonal)
Anti-GFAP Mouse (monoclonal)
Anti-βIII-tubulin Mouse (monoclonal)
Anti β-actin Mouse (monoclonal)
Anti-CD31 Mouse (monoclonal)
Anti-PDGFβR1 Mouse (monoclonal)
Anti-NG2 Mouse (monoclonal)
Anti-S100β Mouse (monoclonal)
Anti-VEGF Mouse (monoclonal)
Anti-albumin Mouse (monoclonal)
Anti-β2Microglobulin Mouse (monoclonal)
IHC, immunohistochemistry; WB, Western blot.Alexa Fluor 568-labelled donkey anti-goat (all from
Invitrogen, 1:1000 dilution for IF).
SDS-PAGE and western blotting
Protein lysates were prepared from cortex, hippocampus
and sub-ventricular zone of rat brains (n =3), human
serum and CSF as described previously [42]. 20 μg
protein samples were separated on 10–20% Nu-PAGA
Bis-tris (Bis (2-hydroxyethyl)-amino-tris (hydroxymethyl)-
methane) gradient gels (1.25 M Bis-Tris pH 6.4, 30% acryl-
amide/bis), run with NuPAGE® MES SDS running buffer
(Lifetechnologies) and transferred to 0.2 μm pore size
PVDF membranes (Invitrogen). Membranes were incu-
bated with the appropriate primary antibody in blocking
buffer for 24 h at 4°C and then washed three times with
0.1 M tris saline buffer containing 1% Tween 20 (TBST)
followed by incubation for 1 hour at room temperature
with HRP-conjugated secondary antibodies (anti mouse
IgG (1:3000, DAKO) or anti-rabbit IgG (1:3000; DAKO)
antibodies). Binding was detected with ECL Plus chemi-
luminescence reagents and Hyperfilm ECL (both from
GE Healthcare). Human serum and CSF were available
from a previous study and ethical permission was given
as described [25].
Immunofluorescence (IF)
Sections were blocked using blocking buffer (0.1 M PBS,
0.3% Triton X100, 10% normal donkey serum) for 1 h at
room temperature, then incubated overnight at 4°C with
primary antibody diluted in blocking buffer. Alexa
Fluor-conjugated secondary antibodies were used for
detection and samples counterstained with 4′6-diami-
dino-2-phenylindole (DAPI, Sigma). Sections were then
mounted on glass slides with coverslips using FluorSave
(Calbiochem).Dilution Supplier/cat.number
1: 200 for IHC Abcam (Ab30760)
1:100 for WB
1: 1000 for IHC Abcam (ab93438)
1:1000 for IHC Sigma (G3893 Clone G-A-5)
1:1000 for IHC Millipore (clone 2G10, neuronal | 05–559)
1:10000 for WB Sigma (clone AC-74, A5316)
1: 1000 for IHC Abcam (ab9498)
1: 1000 for IHC Abcam (ab69506)
1: 1000 for IHC Abcam (ab50009)
1: 1000 for IHC Abcam (ab4066)
1: 1000 for IHC Abcam (ab46154)
1:1000 for WB Abcam (ab92469)
1:1000 for WB Abcam (759)
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Bright field images were taken and quantified using
Lucia imaging software and a Leica FW 4000 upright
microscope equipped with a SPOT digital camera. Fluor-
escence images were obtained using a Leica DM6000
wide field fluorescence microscope equipped with a
Leica FX350 camera and x20 and x40 objectives. Images
were taken through several z-sections and de-convolved
using Leica software. A Leica TCS SP2 confocal laser-
scanning microscope was used with x40 and x63 objec-
tives to acquire high-resolution images.
Image and statistics analysis
All experiments were performed in triplicate. RT-PCR
and Western blot images were quantified using ImageJ
software (US National Institutes of Health), normalising
all samples to loading controls. Values in the figures are
expressed as mean ± SEM. To determine statistical sig-
nificance, values were analysed by Student’s t-test. A
probability value of p < 0.05 was considered to be statis-
tically significant.
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